- Home
- SMBK vs CSTL Comparison
SMBK vs CSTL Comparison
Compare SMBK & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SMBK | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.5M | 661.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SMBK | CSTL |
|---|---|---|
| Price | $37.76 | $38.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $38.63 | ★ $38.67 |
| AVG Volume (30 Days) | 67.5K | ★ 423.3K |
| Earning Date | 01-20-2026 | 11-03-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 41.99 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | $188,204,000.00 | ★ $343,530,000.00 |
| Revenue This Year | $22.08 | $1.69 |
| Revenue Next Year | $9.89 | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | ★ 18.22 | 10.15 |
| 52 Week Low | $26.31 | $14.59 |
| 52 Week High | $37.92 | $40.61 |
Technical Indicators
Market Signals| Indicator | SMBK | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 66.37 |
| Support Level | $36.87 | $37.83 |
| Resistance Level | $37.74 | $40.54 |
| Average True Range (ATR) | 0.76 | 1.48 |
| MACD | 0.16 | -0.48 |
| Stochastic Oscillator | 85.49 | 55.89 |
Price Performance
Historical ComparisonAbout SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.